<DOC>
	<DOCNO>NCT02970916</DOCNO>
	<brief_summary>The purpose study ass FOLFIRI+aflibercept efficacy patient without ACE polymorphism term Progression-free survival ( PFS ) .</brief_summary>
	<brief_title>Phase II Trial Assess FOLFIRI+Aflibercept Efficacy Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With Without ACE Polymorphisms</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Signed date informed consent , willing able comply protocol requirement , 2 . Histologically proven adenocarcinoma colon and/or rectum , 3 . Metastatic disease confirm . 4 . Existence least one measurable unidimensional lesion use CT MRI base RECIST criterion , version 1.1 5 . Patients metastatic colorectal cancer ( mCRC ) resistant progress oxaliplatincontaining regimen . 6 . Age ≥18 year 7 . World Health Organization ( WHO ) Performance status ( PS ) 02 , 8 . Hematological status : neutrophil ( ANC ) ≥1.5x109 /L ; platelet ≥100x109 /L ; haemoglobin ≥9g/dL 9 . Adequate renal function : serum creatinine level &lt; 1.5 x ULN 10 . Adequate liver function : serum bilirubin ≤1.5 x upper normal limit ( ULN ) , alkaline phosphatase ( ALP ) &lt; 5xULN 11 . Proteinuria &lt; 2+ ( dipstick urinalysis ) ≤1g/24hour . 12 . Regular followup feasible . 13 . For female patient childbearing potential , negative serum pregnancy test 14 . Female patient must commit use reliable appropriate method contraception least three month end study treatment ( applicable ) . Male patient partner childbearing potential must agree use contraception addition partner use another contraceptive method trial . 1 . Uncontrolled hypercalcemia , 2 . Preexisting permanent neuropathy ( NCI grade &gt; 2 ) 3 . Uncontrolled hypertension ( define systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , history hypertensive crisis , hypertensive ncephalopathy , 4 . Concomitant protocol unplanned antitumor therapy ( e.g . chemotherapy , molecular target therapy , immunotherapy ) , 5 . Treatment investigational medicinal product within 28 day prior study entry . 6 . Other serious uncontrolled nonmalignant disease , 7 . History evidence upon physical examination CNS metastasis unless adequately treat ( e.g . non irradiated CNS metastasis , seizure control standard medical therapy ) , 8 . Known Gilbert 's syndrome 9 . Intolerance atropine sulfate loperamide 10 . Known dihydropyrimidine dehydrogenase deficiency 11 . Treatment CYP3A4 inducer unless discontinue &gt; 7 day prior inclusion 12 . Any follow 3 month prior inclusion : grade 34 gastrointestinal bleeding ( unless due resect tumor ) , treatment resistant peptic ulcer disease , erosive esophagitis gastritis , infectious inflammatory bowel disease , diverticulitis . 13 . Other concomitant previous malignancy , except : i/ adequately treat insitu carcinoma uterine cervix , ii/ basal squamous cell carcinoma skin , iii/ cancer complete remission &gt; 5 year , 14 . Any serious uncontrolled nonmalignant disease , major surgery traumatic injury within last 28 day 15 . Pregnant breastfeed woman , 16 . Patients know allergy excipient study drug , 17 . History myocardial infarction and/or stroke within 6 month prior inclusion , NYHA class III IV congestive heart failure 18 . Bowel obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>FOLFIRI</keyword>
	<keyword>aflibercept</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>ACE polymorphism</keyword>
</DOC>